Neurodevelopmental Disorders

Genomic Diagnosis of Neurodevelopmental Disorders

Neurodevelopmental disorders are the single largest category of referrals for clinical genetic testing. Exome and genome sequencing have transformed a multi-year diagnostic odyssey into a definitive molecular answer for 27–41% of patients.

When to Test

Genetic testing should be considered early in the evaluation of any child or adult presenting with unexplained neurodevelopmental features. The traditional approach of sequential single-gene or panel testing delays diagnosis and increases cost. Current guidelines from the ACMG recommend exome or genome sequencing as a first- or second-tier test for:

• Global developmental delay / intellectual disability — particularly when dysmorphic features, congenital anomalies, or family history suggest a genetic etiology
• Autism spectrum disorder — especially with co-occurring intellectual disability, regression, or epilepsy
• Epilepsy — unexplained seizures with onset before age 5, or drug-resistant epilepsy at any age
• Movement disorders — childhood-onset dystonia, ataxia, or spasticity of unclear etiology
• Neurodegenerative presentations — progressive loss of milestones suggesting a metabolic or genetic cause

Diagnostic Yield by Phenotype

Clinical Presentation	ES/GS Yield	Notes
Intellectual disability (syndromic)	35–50%	Higher yield with dysmorphic features
Intellectual disability (non-syndromic)	20–30%	Consider trio analysis
Autism spectrum disorder	10–30%	Yield higher with ID + ASD
Epilepsy (early onset)	25–45%	Epileptic encephalopathies yield highest
Developmental delay (global)	27–41%	ACMG Tier 1 indication
Cerebral palsy (atypical)	15–30%	Genetic mimics of CP increasingly recognized
Movement disorders (childhood)	20–40%	Dystonia, ataxia, chorea

Testing Strategy

The highest diagnostic yields in NDD come from trio exome or genome sequencing — testing the affected individual alongside both biological parents. This approach enables confident identification of de novo variants, which account for roughly half of all pathogenic findings in neurodevelopmental phenotypes.

Impact on Management

A molecular diagnosis in NDD changes clinical management in 30–65% of cases. This is not just a label — it directly affects care:

• Medication changes: Avoiding contraindicated drugs (e.g., sodium channel blockers in SCN1A-related Dravet syndrome), starting targeted therapies
• Surveillance protocols: Cardiac screening, renal monitoring, endocrine follow-up based on the specific genetic condition
• Recurrence risk counseling: Accurate risk estimates for future pregnancies — de novo vs. inherited changes the math entirely
• Ending the odyssey: No more empiric workups, exploratory procedures, or cycling through specialists without a unifying diagnosis
• Access to clinical trials: Many gene-specific therapies (antisense oligonucleotides, gene therapy) require a confirmed molecular diagnosis for enrollment

The Payer Case

Neurodevelopmental disorders represent one of the strongest ROI arguments for early genetic testing. Undiagnosed NDD patients generate disproportionate utilization — MRI, EEG, metabolic panels, specialist referrals, empiric medication trials — that a single genetic test can render unnecessary. Published models show that early exome/genome sequencing in NDD is cost-effective or cost-saving compared to the traditional sequential testing approach, with break-even typically reached within 12–18 months of avoided downstream workup.